Proteostasis Therapeutics Appoints Dr. Badrul Chowdhury, Former FDA Director of Pulmonology, Allergy, and Rheumatology, to Board of Directors

Monday, May 13, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

BOSTON, May 13, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced that Badrul A. Chowdhury, M.D., Ph.D.,

has been appointed to the Company's Board of Directors. Dr. Chowdhury is Senior Vice President and Chief Physician-Scientist, Respiratory Inflammation and Autoimmunity (RIA) Late Stage, R&D Biopharmaceuticals, at AstraZeneca.  He was previously Director of the Division of Pulmonary, Allergy, and Rheumatology Products at the U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER).

"Dr. Chowdhury has deep expertise as a regulatory strategist, including having presided over the FDA approvals of the current standard-of-care CFTR modulators.  With a broad view across many diseases, including CF, his counsel will be invaluable to PTI as we advance our CF pipeline toward launching our Phase 3 program in mid-2020. We are thrilled to welcome him to the PTI board of directors," said Meenu Chhabra, President and Chief Executive Officer of Proteostasis.

"With its next generation CFTR modulators, Proteostasis has demonstrated the promise of becoming a highly-credible new entrant into the CF marketplace," commented Dr. Chowdhury.  "The CF community has a resounding need for more options to address issues that include patient access, tolerability and durability of treatment. I look forward to contributing as a director to PTI's mission of bringing more treatment options to patients with cystic fibrosis."

Dr. Chowdhury practiced medicine for more than a decade and has more than two decades of regulatory leadership experience. Prior to joining AstraZeneca in April 2018, Dr. Chowdhury served at the FDA for 21 years, where he held numerous leadership roles. His previous roles at the FDA include Medical Team Leader, Division of Pulmonary and Allergy Drug Products, CDER, and Medical Officer, Division of Pulmonary Drug Products, CDER. Dr. Chowdhury has a M.B., B.S. in Medicine from University of Dhaka, Dhaka Medical College, Bangladesh, and a Ph.D. in Immunology from Memorial University of Newfoundland, Canada. He completed his residency training in Internal Medicine at the Wayne State University School of Medicine, Detroit, Michigan, and a fellowship in Allergy and Immunology at the National Institutes of Health's, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, and is double board certified in Internal Medicine and Allergy and Immunology.

About Proteostasis Therapeutics, Inc.

Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis and other diseases caused by dysfunctional protein processing. Headquartered in Boston, MA, the Proteostasis Therapeutics team focuses on identifying therapies that restore protein function. For more information, visit www.proteostasis.com.

Safe Harbor

To the extent that statements in this release are not historical facts, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Words such as "aim," "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements.  Examples of forward-looking statements made in this release include, without limitation, statements regarding the potential of our proprietary combination therapies for the treatment of CF, the potential benefit to patients of our proprietary combination therapies, expected presentations and expected timing of the initiation of, patient enrollment in, data from, the completion of, our clinical studies and cohorts for our clinical programs, including our planned Phase 3 program, and our expectations regarding our new board member.  Forward-looking statements made in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we, therefore cannot assure you that our plans, intentions, expectations or strategies will be attained or achieved.  Such risks and uncertainties include, without limitation, the possibility final or future results from our drug candidate trials (including, without limitation, longer duration studies) do not achieve positive results or are materially and negatively different from or not indicative of the preliminary results reported by the Company (noting that these results are based on a small number of patients and small data set), uncertainties inherent in the execution and completion of clinical trials (including, without limitation, the possibility that FDA comments delay, change or do not permit trial commencement, or intended label, or the FDA requires us to run cohorts sequentially or conduct additional cohorts or pre-clinical or clinical studies), in the enrollment of CF patients in our clinical trials in a competitive clinical environment, in the timing of availability of trial data, in the results of the clinical trials, in possible adverse events from our trials, in the actions of regulatory agencies, in the endorsement, if any, by therapeutic development arms of CF patient advocacy groups (and the maintenance thereof), and those set forth in our Annual Report on Form 10-K for the year ended December 31, 2018 and our other SEC filings.  We assume no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACTS:

Investors:David Pitts / Claudia StyslingerArgot Partners212.600.1902david@argotpartners.com / claudia@argotpartners.com 

Media:David RosenArgot Partners212.600.1902david.rosen@argotpartners.com

Cision View original content:http://www.prnewswire.com/news-releases/proteostasis-therapeutics-appoints-dr-badrul-chowdhury-former-fda-director-of-pulmonology-allergy-and-rheumatology-to-board-of-directors-300848640.html

SOURCE Proteostasis Therapeutics, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store